Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ESRRG | P62508 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.43 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11074386 | 0.84 | NPC1 (0.52) | EPHX2POLBESRRGKDM4EMAPT | |
| SCHEMBL5940572 | 0.84 | HTT (0.52) | EPHX2POLBESRRGKDM4EMAPT | |
| SCHEMBL688944 | 0.83 | POLB (0.70) | EPHX2POLBESRRGKDM4EMAPT | |
| SCHEMBL854187 | 0.80 | LMNA (0.53) | EPHX2POLBESRRGKDM4EMAPT | |
| SCHEMBL4023884 | 0.78 | PHLPP2 (0.48) | EPHX2POLBESRRGKDM4EMAPT | |
| SCHEMBL688943 | 0.78 | MAPT (0.47) | EPHX2POLBESRRGKDM4EMAPT | |
| Tert-Butylamine SCHEMBL7372525 | 0.77 | LMNA (0.50) | EPHX2POLBESRRGKDM4EMAPT | |
| SCHEMBL21335533 | 0.76 | MAPT (0.49) | EPHX2POLBESRRGMAPTLMNA | |
| SCHEMBL13270520 | 0.75 | JAK2 (0.57) | EPHX2POLBESRRGKDM4EMAPT | |
| SCHEMBL22987120 | 0.75 | MAPT (0.49) | EPHX2POLBESRRGKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603387-B2 | Duocarmycin ADCs showing improved in vivo antitumor activity | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2020-03-31 | — | — | US | disclosed |
| US-20180140711-A1 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | SYNTHON BIOPHARMACEUTICALS B.V. (NL) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140711-A1 | DUOCARMYCIN ADCS SHOWING IMPROVED IN VIVO ANTITUMOR ACTIVITY | CD38, BRCA1, TP53 | EPHX2 4522/4885POLB 2848/4885ESRRG 2639/4885 |
| US-10603387-B2 | Duocarmycin ADCs showing improved in vivo antitumor activity | CD38, BRCA1, TP53 | EPHX2 4522/4885POLB 2848/4885ESRRG 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.